

Special Issue

Biomarker, Phenotyping and Therapeutics for Asthma

Message from the Guest Editor

Asthma is one of the most prevalent chronic airway diseases worldwide, characterised by marked clinical variability and substantial biological heterogeneity. The diagnosis of asthma remains challenging, with no single definitive test, contributing to misdiagnosis and inappropriate treatment. Furthermore, although precision medicine has emerged for severe asthma through the introduction of biologic therapies, this applies to only a minority of patients; the majority continue to be managed with one-size-fits-all approaches that overlook the heterogeneity of individual disease endotypes.

This Special Issue seeks to bring together cutting-edge mechanistic and translational research that bridges fundamental biology with clinical application. We welcome studies that (i) identify and validate novel biomarkers for asthma diagnosis, endotyping and disease monitoring; (ii) provide experimental insights into asthma pathophysiology across immune, epithelial and airway mechanical pathways; (iii) apply multi-omics, exhaled breath analysis and advanced physiological measures to refine phenotyping and uncover therapeutic targets; (iv) explore novel molecular pathways and therapeutic strategies.

Guest Editor

Dr. Ran Wang

Division of Immunology, Immunity to Infection and Respiratory Medicine, NIHR Manchester Biomedical Research Centre, Manchester, UK

Deadline for manuscript submissions

30 April 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/253965

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).